Kornimate/medical-research-clean huggingface dataset:
effects of dpp4 inhibition on covid-19

Conditions: Coronavirus Infection; Type 2 Diabetes

Summary: the purpose of this research is to see if the dpp4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the covid-19 infection


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (t2dm) as per american diabetes association (ada) guidelines * age ≥ 18 * confirmed covid-19 * mild covid-19 defined as any of the following: fever, malaise, cough, headache, sore throat, myalgia, nasal congestion, diarrhea * moderate covid-19 is defined as \> 2 of the following in non-intubated patients: any symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with bilateral ground glass opacities or bilateral consolidations, spo2 \<90% up to 5l nasal cannula (nc) * no additional signs or symptoms of severe covid-19. exclusion criteria: * type 1 diabetes mellitus (t1dm) diabetes, as per ada guidelines * history of diabetic ketoacidosis (dka) * history of acute pancreatitis * chronic or acute renal failure with estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73 m2 exclusion criteria: t1dm diabetes, as per ada guidelines, history of dka, history of acute pancreatitis; chronic or acute renal failure with egfr \< 30 ml/min/1.73 m2

Keywords: covid-19 sars-cov 2 dpp4 type 2 diabetes
accuracy of pulp sensibility test on teeth with deep periodontal pocket

Conditions: Periodontitis, Localized Aggressive; Periodontal Diseases; Endodontic Disease; Endodontic Inflammation; Periodontal Pocket; Periodontal Inflammation; Periodontal Attachment Loss; Periodontal Bone Loss; Periodontitis

Summary: the aim of this study is to evaluate the accuracy of pulp test in teeth presenting with deep periodontal pocket. the null hypothesis is no significant effect of periodontitis on the accuracy of pulp test.

the aim of this study is to evaluate the accuracy of pulp test in teeth presenting with deep periodontal pocket. all patients who need root canal treatment would be screened to determine the periodontal condition for possible involvement in this study. they would be grouped into two groups, normal and periodontitis group. included teeth will be dried with 4x4 gauze then tested with a cold test using endo-ice and electric pulp tester (ept). similar or adjacent teeth with no caries, restorations, or a history of the previous injury will be used as controls for that patient. upon accessing the tooth, no bleeding was counted as necrotic and any presence of blood was counted as a vital pulp

Eligibility criteria:
inclusion criteria: * patients from 18 to 40 years old. * periodontitis grade ii, iii and iv * non-traumatized teeth. * no prior non-surgical root canal treatment (ns rct). exclusion criteria: * periodontitis grade i. * patients with medically compromising conditions (asa iii and above). * trauma within the last six months. * partially necrotic pulps. * previously endodontically treated or initiation of treatment will be excluded.

Keywords: periodontitis endodontic endo ice electric pulp tester (ept).
the registration program of brca1/2 gene

Conditions: Breast Cancer

Summary: purpose: 1. screening of large samples is to search the gene mutation of the breast cancer susceptibility gene (brca1 and brca2) in chinese high risk group. 2. to build the breast cancer brca1/2 mutation database of chinese group. 3. to build the hazard model of breast cancer brca1/2 mutation of chinese group.

it is the first large-scale and systematic study that fully recognize and review on the mutation spectrum of brca1/2 and the risk of breast cancer in chinese high risk group, it will be a landmark research of susceptibility genes in chinese breast cancer.

Eligibility criteria:
chinese genetic/familial breast cancer patients, and its first or second degree relatives with breast cancer (female or male). the selection will be based on nccn clinical practice guidelines in oncology (genetic/familial high-risk assessment: breast and ovarian). inclusion criteria: patients: it must be from independent family and meet the one or more of the following conditions. 1. patients' age at diagnosis: 45 years or younger. 2. patients' age at diagnosis: 50 years or younger. 3. breast cancer patients: it must meet the one or more of the following family medical histories. 3.1 patients' age at diagnosis: 50 years or younger, and the one or more of the next of kin has breast cancer. 3.2 patients' age at diagnosis: any of age, and the one or more of the next of kin has breast cancer that its age at diagnosis was 50 years or younger. 3.3 patients' age at diagnosis: any of age, and the two or more of the next of kin have breast cancer that its age at diagnosis was 50 years or younger. 3.4 patients' age at diagnosis: any of age, and the one or more of the next of kin has epithelial ovarian cancer. 3.5 patients' age at diagnosis: any of age, and the two or more of the next of kin have pancreatic cancer and/or prostate cancer (gleason grading\>7, any of age). 3.6 patients' age at diagnosis: any of age, and the one or more of the close-male relatives has breast cancer. 4. triple negative patients' age of onset: 60 years or younger. 5. patients: male and have breast cancer. patients' first or second degree relatives are brca1/2 mutation carrier (1-5 people): first or second degree female adult relatives of patients (age: 18 years or older), it will be selected from the same paternal or maternal side according to the family disease. first or second degree male relatives of patients have breast cancer. exclusion criteria: n/a.

Keywords: brca1/2 gene mutation breast cancer chinese high risk group
evaluation of the management of acute appendicitis before emergency department in children: a prospective study

Conditions: Appendicitis

Summary: acute appendicitis is the first visceral surgical emergency in pediatrics with about 30,000 cases in children having been described in france. it concerns 0.3% of children under 15 with a maximum frequency between 8 and 13 years of age. acute appendicitis has a significant morbidity rate of 8% and a mortality rate under 0.1%. 10 to 25% of the children admitted to emergency rooms for abdominal pain have appendicitis. in 20 to 30% of the cases, the initial symptoms are atypical, which explains the difficulty in diagnosing. the purpose of our study is to evaluate the quality of general practitioners in the diagnosis of acute appendicitis, its severity and the diagnostic criteria used. furthermore, it is not as easy to evaluate pain or examine a complaint in children as it is in adults. appendicectomy is the treatment of choice for all acute appendicitis. the importance of early diagnosis and treatment is, therefore, essential. many predictive diagnostic scores have been studied over the years. the pediatric appendicitis score (pas) using typical symptoms of acute appendicitis and biological items was published in 2002. nowadays, it is still considered as a reference and has been validated by other studies. most of the patients suffering from abdominal pain first consult their general practitioner.


Eligibility criteria:
inclusion criteria: * child \<16 years * abdominal symptoms * consulting in the pediatric emergency department of limoges university center. exclusion criteria: * child \>=16 years
study ffr116364, a placebo-controlled study of gw685698x in paediatric subjects with perennial allergic rhinitis

Conditions: Rhinitis, Allergic, Perennial

Summary: efficacy and safety of gw685698x (55 µg/day, q.d.) nasal spray over a period of 2 weeks in japanese paediatric subjects ages 6 to \< 15 years with perennial allergic rhinitis will be evaluated compared with placebo.


Eligibility criteria:
inclusion criteria: * informed consent * 6 to \<15 years of age, male or eligible female (females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control), outpatient * diagnosis of perennial allergic rhinitis: a positive test response to house dust and/or dust mites on serum antigen-specific ige antibody test at visit 1. one year or more clinical history of perennial allergic rhinitis. a positive test result on nasal eosinophil count at visit 1/1a. * either subject's parent/guardian who signed icf or subject is able to complete assessments on the patient diary through the study. * alt \< 2xuln; alkaline phosphatase and bilirubin \<= 1.5xuln * average of 3tnss is \>= 4.0 in the last consecutive 4 days prior to visit 2. * completion of the patient diary on \>= 3 days of the last consecutive 4 days prior to visit 2 exclusion criteria: * has a seasonal pollen as an allergen * a nose disorder that could affect the assessment of the study medication or eye or nose surgery (within 3 months prior to visit 1) * bacterial or viral infection of upper respiratory tract or eye * concurrent disease/abnormalities: clinically significant uncontrolled disease * known hypersensitivity to corticosteroids or any excipients in the investigational product * has recent participation in a study and/or exposure to an investigational study drug within 3 months prior to visit 1 * use of the following medication and/or its combination drug within the specified time: anti-ige (within 6 months prior to visit 1), immunosuppressive medications or systemic corticosteroids (within 8 weeks prior to visit 1), topical corticosteroids (within 4 weeks prior to visit 1), immunotherapy or nonspecific allassotherapy which was initiated, discontinued or changed its dose within 4 weeks prior to visit 1 * affiliation with investigator's site: relative or employee * history of alcohol or drug abuse, children in care or in the opinion of the investigator (sub-investigator), inappropriate to be enrolled in the study. * average of 3tnss is \>= 8.0 in the last consecutive 4 days prior to visit 2. * bacterial or viral infection of upper respiratory tract or eye during the screening period.
study on the relative dose intensity of parp inhibitors in real-life on a population of patients over 70 years with advanced ovarian cancer

Conditions: Ovarian Cancer

Summary: poly(adp-ribose) polymerase (parp) inhibitors are anti-cancer treatments that induce preferential tumor cell death. their efficacy has been demonstrated in many tumor models, primarily in advanced ovarian cancer. parp inhibitors also exhibit a particular toxicity, damaging the hematopoietic tissue. with age, pharmacokinetic changes or a reduction in medullary cavity may increase these toxicities and may lead to dose reductions/postponements or premature discontinuation of parp inhibitors, which may impact the efficacy of treatment. close biological monitoring must be carried out to limit these toxicities, in most cases anemia, thrombocytopenia and neutropenia. until now, the geriatric factors impacting the tolerance and uptake of parp inhibitors in the elderly patient population with advanced ovarian cancer are not clearly established. it is therefore necessary to have prospective real-life data in order to support patients in a decision-making process on whether or not to continue such treatments. parib-old-pro² will evaluate the association between various clinical, biological, and geriatric factors and the relative dose intensity (rdi) of therapy by parp inhibitors. this is a prospective, multicenter longitudinal and non-interventional study and will involve a population of 50 patients, aged 70 years and elder, with advanced ovarian cancer who are scheduled to start a therapy with parp inhibitors for the first time. the aim of the study is to better understand the effects of parp inhibitors on a elderly population, knowledge of the genetic and clinical determinants of parp inhibitors toxicity in this specific population and an optimal management of this therapy related adverse events in order to maintain an rdi.


Eligibility criteria:
inclusion criteria: * age ≥ 70 years * histologically or cytologically confirmed diagnosis of advanced ovarian cancer (figo stage iii or iv) * parp inhibitors -naive patient who need to initiate maintenance treatment with parp inhibitors for the first time (according the the marketing authorization) * patient with a life expectancy of more then 3 months * informed patient which does not oppose to participate to the study exclusion criteria: * prior treatment with parp inhibitors * patient incapable to take oral tablets/capsules * participation in a drug trial that does not authorize concurrent participation in another trials * person unable to attend scheduled examinations/appointments as part of routine care for geographical, social or psychological reasons * concomitant cancer or f cancer history (other than those included in the inclusion criteria) treated and considered cured for less than 2 years. however, patients with the following pathologies are eligible: * basal cell carcinoma or non-invasive cutaneous squamous cell carcinoma * stage 1b or less cervical carcinoma * non-invasive superficial bladder cancer

Keywords: cancer ovary parp inhibitors toxicity elder patients
feasibility and pilot study of a rule-based chatbot application for adolescents with anxiety symptoms

Conditions: Anxiety

Summary: the goal of this feasibility and pilot study is to investigate the feasibility and preliminary clinical effects of a new rule-based chatbot intervention for adolescents with anxiety symptoms. the main questions are: * is the intervention feasible for adolescents who are experiencing anxiety symptoms? * how do the adolescents experience the use of the intervention? * does the intervention lead to a reduction in anxiety symptoms? * does the intervention lead to a clinically significant reliable improvement at functional level?

anxiety is one of the most common psychiatric disorders and the anxiety symptoms typically onsets in adolescence. the anxiety symptoms may be persistent into adulthood, leading to a poorer life quality and function impairments. the goal is to prevent the development of anxiety and comorbid disorders, as well as function impairment due to anxiety symptoms. this study wishes to investigate the feasibility and preliminary clinical effects of a digital intervention in an open pre-post and 3 months follow up study. the intervention consists of a rule-based click-chatbot, combined with therapist-guidance. this study will recruit n = 30 adolescents from norway from age 13 up to 16 years old to investigate the feasibility and preliminary clinical effects of a rule-based click chatbot-intervention, and whether it causes a reduction in anxiety symptoms and increases of life functioning. if the intervention is feasible with promising results, the study will serve as a first step to a future randomized controlled trial.

Eligibility criteria:
inclusion criteria: * reporting anxiety symptoms that hinders them in participating in daily activities * spending time trying to avoid these anxiety symptoms * aged 13 and up to 16 years * can read norwegian exclusion criteria: * clinical cut-off on ocd subscale on rcads-47\> 10, * clinical cut-off on depression subscale on rcads-47 \> 16, * ongoing treatment * extensive reading/writing difficulties * extensive concentration problems

Keywords: adolescents anxiety chatbot intervention technology-delivered intervention
effect of an inhaled glucocorticosteroid (ics) on endothelial dysfunction in cigarette smokers

Conditions: Tobacco Abuse Smoke

Summary: the hypothesis underlying the proposed study is that the blunted endothelium-dependent vasodilation seen in the airway of current smokers is also present in the brachial artery, and that the same inhaled corticosteroid (ics) treatment regime that reversed endothelial function in the airway of current smokers will also restore endothelium-dependent relaxation in the brachial artery. non-smokers will be used as controls and will not receive any intervention or treatment.

cigarette smoking can lead to systemic endothelial dysfunction. since the airway circulation is exposed to a high concentration of cigarette smoke constituents, we reasoned that airway vascular endothelial dysfunction could be present in healthy smokers without systemic endothelial dysfunction. the purpose of this study was to compare airway and systemic endothelial function and measure markers of systemic inflammation in lung-healthy current smokers. since endothelial dysfunction in smokers has been related to systemic inflammation, we also investigated its response to an inhaled glucocorticosteroid (ics). vascular endothelial function was assessed in the airway by the airway blood-flow (qaw) response to inhaled albuterol (δqaw) and in the extrapulmonary circulation by brachial arterial flow-mediated vasodilation (fmd). venous blood was collected for c-reactive protein and il-6. qaw was measured with a noninvasive inhaled soluble gas uptake technique. the uptake of the gas from the anatomical deadspace reflecting airways perfused by the airway circulation was quantitated. qaw was express as μl/min normalized for anatomical deadspace: μl/min/ml.

Eligibility criteria:
inclusion criteria: for both healthy non-smokers and healthy current smokers: normal spirometry healthy current smokers: history of \>10 pack-year smoking exclusion criteria: women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women. cardiovascular disease and/or use of cardiovascular medications. subjects with known beta-adrenergic agonist or nitroglycerin intolerance. a physician diagnosis of chronic airway disease (asthma, copd, bronchiectasis, cystic fibrosis). acute respiratory infection within four weeks prior to the study. use of any airway medication. fev1 \ 30.

Keywords: smokers inhaled corticosteroids brachial flow airway blood flow albuterol spirometry endothelial dysfunction
impact of systematic infants vaccination against rotavirus on gastroenteritis hospitalization: a prospective study in brest district, france.

Conditions: Rotavirus Gastroenteritis

Summary: universal rotavirus vaccination program for infants born in brest after february 2007, applied by the centers for maternal and infant health protection, pediatricians and general practitioners. prospective surveillance of hospitalizations for gastroenteritis within the pediatric units of brest university hospital with systematic testing for rotavirus. evaluation of the impact of the vaccination program on rotaviral gastroenteritis hospitalizations from 2007-2008 and 2008-2009, by comparison with epidemiological data from 2002-2007 in the absence of vaccination. the principal judgement criterion is the number of pediatric hospitalizations for rotaviral gea during the 2008-2009 epidemic in children a) under the age of 2 and b) residing in the suburbs of brest.


Eligibility criteria:
inclusion criteria: * infants aged 6 to 12 weeks * born in brest district, france * born between feb 01, 2007 and nov 19, 2009 exclusion criteria: * contraindication to rotavirus vaccine

Keywords: prevention rotavirus vaccine gastroenteritis systematic vaccination infants aged 6 to 12 weeks
opioid prescribing in the emergency department for sickle cell disease

Conditions: Discrimination, Racial; Pain Management; Emergency Medicine; Sickle Cell Disease

Summary: this study consists of a clinical vignette presented to emergency physicians asking them what they would prescribe to a patient with acute abdominal pain.


Eligibility criteria:
inclusion criteria: * being a emergency physician exclusion criteria: * working outside of europe.
evaluating the effectiveness of 2 surgical skin preparation methods in reducing surgical wound drainage after total hip or knee replacement

Conditions: Drainage

Summary: surgical skin complications can be costly and could contribute to extended in-patient stay following total joint replacement or even the need for re-admission. if efficacy in reducing the incidence of post-operative wound drainage and, in turn, surgical wound complications can be demonstrated, it may also reduce the length of hospital stay and the need for revision surgery or readmission. the aim of this research is to investigate the incidence of post-operative wound drainage following elective total joint arthroplasty using two surgical skin preparation protocols.


Eligibility criteria:
inclusion criteria: 1. subjects who are able and willing to provide informed consent 2. male and non-pregnant, non-lactating, postmenopausal or surgically sterilized female subjects between the ages of 18-80 years old. 3. subjects deemed able to comply with study visit schedule and procedures. 4. subjects undergoing elective total hip arthroplasty or elective total knee arthroplasty. exclusion criteria: 1. subjects undergoing revision, unicompartmental, bilateral total knee arthroplasty or bilateral total hip arthroplasty. 2. subjects undergoing non-elective total joint procedures. 3. pregnant, lactating females, or females of childbearing potential not willing to practice an effective method of contraception. 4. subjects with known allergies or previous skin reaction to iodine povacrylex
study of navtemadlin add-on to ruxolitinib in jak inhibitor-naïve patients with myelofibrosis who have a suboptimal response to ruxolitinib

Conditions: Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis; MF

Summary: this clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. subjects will start by receiving ruxolitinib alone in the run-in period. those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. randomized means that subjects will be assigned to a group by chance, like a flip of a coin. the study is blinded, meaning the subjects, doctors, central endpoint assessors and sponsor will not know which add on treatment (navtemadlin or navtemadlin placebo) the subject is receiving.


Eligibility criteria:
inclusion criteria for ruxolitinib alone period: * confirmed diagnosis of pmf, post-pv mf, or post-et mf, as assessed by the treating physician according to the world health organization (who) criteria * high, intermediate-1, intermediate-2 risk category international prognosis system score (ipss) * eastern cooperative oncology group (ecog) performance status of 0 to 2 * jak-inhibitor treatment naive exclusion criteria for ruxolitinib alone period: * prior splenectomy * splenic irradiation within 3 months prior to the first dose * prior bcl-xl, bet, mdm2, pi3k, pim, or xpo1 inhibitors therapy or p53-directed therapy * eligible for bone marrow transplant * peripheral blood or bone marrow blast count ≥ 10 percent inclusion criteria for randomized period: * pmf, post-pv mf, or post-et mf that is tp53wt as assessed by central testing * ecog performance status of 0 to 2 * treatment with a stable dose of ruxolitinib * suboptimal response to run-in ruxolitinib treatment exclusion criteria for randomized period: * elevated white blood cell count that doubles (or more) during ruxolitinib treatment and exceeds 50 × 10\^9/l * peripheral blood or bone marrow blast count ≥ 10 percent

Keywords: navtemadlin krt-232 ruxolitinib poiesis tp53 suboptimal response sub-optimal response